scholarly journals CXCL13 CSF level inversely correlates with duration of disease in primary progressive multiple sclerosis

2016 ◽  
Vol 85 (4) ◽  
pp. 302-304
Author(s):  
Jacek Losy ◽  
Piotr Iwanowski ◽  
Elżbieta Kaufman ◽  
Marlena Wójcicka
Keyword(s):  
Multiple Sclerosis ◽  
Serum Levels ◽  
Progressive Multiple Sclerosis ◽  
Control Group ◽  
Primary Progressive Multiple Sclerosis ◽  
Primary Progressive ◽  
Cxcl13 Level ◽  
Relapsing Remitting ◽  
Duration Of Disease ◽  
And Control

Chemokines are important factors in the immunopathogenesis of multiple sclerosis. The objective of the study was to examine the CSF and serum levels of CXCL13 and CCL5 chemokines in primary progressive MS, compare results with relapsing remitting MS and control group with other noninflammatory neurological disorders. The levels of chemokines was measured by ELISA method. The CXCL13 CSF levels in PP and RR MS were higher in comparison with control group, without significant differences between these podgroups. Additionally CXCL13 level in PP MS inversely correlated with duration of the disease. CCL5 CSF level was also significantly higher in PP MS in comparison with control group. The results demonstrate involvement of CXCL13 and CCL5 chemokines in the immunopathogenetic mechanisms of primary progressive MS.

CXCL13 CSF level inversely correlates with duration of disease in primary progressive multiple sclerosis

10.20883/169 ◽  
2016 ◽  
Vol 85 (4) ◽  
pp. 302
Author(s):  
Jacek Losy ◽  
Piotr Iwanowski ◽  
Elżbieta Kaufman ◽  
Marlena Wójcicka
Keyword(s):  
Multiple Sclerosis ◽  
Serum Levels ◽  
Progressive Multiple Sclerosis ◽  
Control Group ◽  
Primary Progressive Multiple Sclerosis ◽  
Primary Progressive ◽  
Cxcl13 Level ◽  
Relapsing Remitting ◽  
Duration Of Disease ◽  
And Control

Chemokines are important factors in the immunopathogenesis of multiple sclerosis. The objective of the study was to examine the CSF and serum levels of CXCL13 and CCL5 chemokines in primary progressive MS, compare results with relapsing remitting MS and control group with other noninflammatory neurological disorders. The levels of chemokines was measured by ELISA method. The CXCL13 CSF levels in PP and RR MS were higher in comparison with control group, without significant differences between these podgroups. Additionally CXCL13 level in PP MS inversely correlated with duration of the disease. CCL5 CSF level was also significantly higher in PP MS in comparison with control group. The results demonstrate involvement of CXCL13 and CCL5 chemokines in the immunopathogenetic mechanisms of primary progressive MS.

Prodrome in relapsing-remitting and primary progressive multiple sclerosis

2019 ◽  
Vol 26 (7) ◽  
pp. 1032-1036 ◽  
Author(s):  
J. M. A. Wijnands ◽  
F. Zhu ◽  
E. Kingwell ◽  
Y. Zhao ◽  
C. Evans ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Progressive Multiple Sclerosis ◽  
Primary Progressive Multiple Sclerosis ◽  
Primary Progressive ◽  
Relapsing Remitting

scholarly journals Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deterioration

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Mario Amatruda ◽  
Maria Petracca ◽  
Maureen Wentling ◽  
Benjamin Inbar ◽  
Kamilah Castro ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Progression ◽  
Progressive Multiple Sclerosis ◽  
Primary Progressive Multiple Sclerosis ◽  
Disease Course ◽  
Primary Progressive ◽  
T2 Lesions ◽  
Relapsing Remitting ◽  
One Year ◽  
Multiple Sclerosis Patients

Abstract The disease course of patients with a confirmed diagnosis of primary progressive multiple sclerosis (PPMS) is uncertain. In an attempt to identify potential signaling pathways involved in the evolution of the disease, we conducted an exploratory unbiased lipidomic analysis of plasma from non-diseased controls (n = 8) and patients with primary progressive MS (PPMS, n = 19) and either a rapid (PPMS-P, n = 9) or slow (PPMS-NP, n = 10) disease course based on worsening disability and/or MRI-visible appearance of new T2 lesions over a one-year-assessment. Partial least squares-discriminant analysis of the MS/MSALL lipidomic dataset, identified lipids driving the clustering of the groups. Among these lipids, sphingomyelin-d18:1/14:0 and mono-hexosylceramide-d18:1/20:0 were differentially abundant in the plasma of PPMS patients compared to controls and their levels correlated with MRI signs of disease progression. Lyso-phosphatidic acid-18:2 (LPA-18:2) was the only lipid with significantly lower abundance in PPMS patients with a rapidly deteriorating disease course, and its levels inversely correlated with the severity of the neurological deficit. Decreased levels of LPA-18:2 were detected in patients with more rapid disease progression, regardless of therapy and these findings were validated in an independent cohort of secondary progressive (SPMS) patients, but not in a third cohorts of relapsing–remitting (RRMS) patients. Collectively, our analysis suggests that sphingomyelin-d18:1/14:0, mono-hexosylceramide-d18:1/20:0, and LPA-18:2 may represent important targets for future studies aimed at understanding disease progression in MS.

scholarly journals Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis

2011 ◽  
Vol 69 (4) ◽  
pp. 590-595 ◽  
Author(s):  
Dóra-Neide Rodrigues ◽  
Renata Alves Paes ◽  
Claudia Cristina Ferreira Vasconcelos ◽  
Jesus Landeira-Fernandez ◽  
Maria Papais Alvarenga
Keyword(s):  
Multiple Sclerosis ◽  
Neuropsychological Tests ◽  
Progressive Multiple Sclerosis ◽  
Primary Progressive Multiple Sclerosis ◽  
Cognitive Profiles ◽  
Primary Progressive ◽  
Immediate Recall ◽  
Relapsing Remitting ◽  
Healthy Control ◽  
Visual Organization

Cognitive impairment is a symptom of multiple sclerosis (MS). Different clinical forms of multiple sclerosis have different cognitive profiles, according to findings of previous studies which used extensive batteries of neuropsychological tests. OBJECTIVE: To investigate cognitive profiles of Brazilian patients with relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) by using a brief battery of neuropsychological tests. METHOD: Sixty-six patients, within 18-65 of age and 3-18 years of education, were paired with healthy control subjects, regarding gender, age, and education level. RESULTS: On Symbol Digit Modalities Test and Hooper Visual Organization Test, cognition was affected in 50% in RRMS and 69% in PPMS. Fluency of "F" was impaired in 24% of RRMS and 81% of PPMS. Immediate recall was affected in 32% of RRMS and in 63% of PPMS; whereas late recall, in 46% of relapsing-remitting and in 69% of primary progressive. CONCLUSION: Cognitive profiles of relapsing-remitting and primary progressive patients are different

Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis

2005 ◽  
Vol 11 (1) ◽  
pp. 13-15 ◽  
Author(s):  
N Wilczak ◽  
G SM Ramsaransing ◽  
J Mostert ◽  
D Chesik ◽  
J De Keyser
Keyword(s):  
Multiple Sclerosis ◽  
Growth Factor ◽  
Disease Duration ◽  
Binding Protein ◽  
Serum Levels ◽  
Progressive Multiple Sclerosis ◽  
Primary Progressive Multiple Sclerosis ◽  
Insulin Like Growth Factor ◽  
Primary Progressive ◽  
Igfbp 3

Using radioimmunoassay we measured serum levels of insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-3 in patients with relapsing multiple sclerosis (MS) and a benign course (Expanded Disability Status Scale (EDSS)≤ 3 despite > 10 years disease duration), relapsing MS with cumulative disability leading to an EDSS score > 4 within 10 years of disease duration, primary progressive MS and healthy controls. We found no differences in IGF-1 and IGFBP-3 serum levels, and the IGF-1/IGFBP-3 ratio between the four groups. However, there was a significant correlation (P=0.005) between IGFBP-3 serum levels and both the progression index of disability and the Multiple Sclerosis Severity Score in patients with primary progressive MS.

scholarly journals Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsing–Remitting and Primary Progressive Multiple Sclerosis

2020 ◽  
Vol 9 (3) ◽  
pp. 863 ◽  
Author(s):  
Federica Murgia ◽  
Lorena Lorefice ◽  
Simone Poddighe ◽  
Giuseppe Fenu ◽  
Maria Antonietta Secci ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Analytical Techniques ◽  
Roc Curves ◽  
Progressive Multiple Sclerosis ◽  
Glutathione Metabolism ◽  
Primary Progressive Multiple Sclerosis ◽  
Primary Progressive ◽  
Relapsing Remitting ◽  
Pathways Analysis

Background: Multiple sclerosis (MS) is a chronic immunemediated disease of the central nervous system with a highly variable clinical presentation and disease progression. In this study, we investigate the metabolomics profile of patients affected by relapsing–remitting MS (RRMS)and primary progressive MS (PPMS), in order to find potential biomarkers to distinguish between the two forms. Methods: Cerebrospinal Fluid CSF and blood samples of 34 patients (RRMS n = 22, PPMS n = 12) were collected. Nuclear magnetic resonance (1H-NMR) and mass spectrometry (coupled with a gas chromatography and liquid chromatography) were used as analytical techniques. Subsequently, a multivariate statistical analysis was performed; the resulting significant variables underwent U-Mann–Whitney test and correction for multiple comparisons. Receiver Operating Characteristic ROC curves were built and the pathways analysis was conducted. Results: The analysis of the serum and the CSF of the two classes, allowed the identification of several altered metabolites (lipids, biogenic amines, and amino acids). The pathways analysis indicated the following pathways were affected: Glutathione metabolism, nitrogen metabolism, glutamine–glutamate metabolism, arginine–ornithine metabolism, phenylalanine, tyrosine and tryptophan biosynthesis etc. Conclusion: The analysis allowed the identification of a set of metabolites able to classify RRMS and PPMS patients, each of whom express different patterns of metabolites in the two biofluids.

Primary progressive multiple sclerosis diagnostic criteria: a reappraisal

2009 ◽  
Vol 15 (12) ◽  
pp. 1459-1465 ◽  
Author(s):  
X. Montalban ◽  
J. Sastre-Garriga ◽  
M. Filippi ◽  
Z. Khaleeli ◽  
N. Téllez ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Diagnostic Criteria ◽  
Disease Duration ◽  
Progressive Multiple Sclerosis ◽  
Added Value ◽  
Oligoclonal Bands ◽  
Primary Progressive Multiple Sclerosis ◽  
Primary Progressive ◽  
Mcdonald Criteria ◽  
Relapsing Remitting

The diagnostic criteria used in primary progressive (PP) and relapsing—remitting (RR) multiple sclerosis (MS) show substantial differences. This introduces complexity in the diagnosis of MS which could be resolved if these criteria could be unified in terms of the requirements for dissemination in space (DIS). The aim of this study was to assess whether a single algorithm may be used to demonstrate DIS in all forms of MS. Five sets of RRMS criteria for DIS were applied to a cohort of 145 patients with established PPMS (mean disease duration: 11 years — PPMS-1): C1: Barkhof—Tintoré (as in 2005 McDonald’s criteria); C2: Swanton et al. (as in JNNP 2006); C3: presence of oligoclonal bands plus two lesions (as in McDonald’s criteria); C4 and C5: a two-step approach was also followed (patients not fulfilling C1 or C2 were then assessed for C3). Two sets of PPMS criteria for DIS were applied: C6: Thompson et al. (as in 2001 McDonald’s criteria); C7: 2005 McDonald criteria. A second sample of 55 patients with less than 5 years of disease duration (PPMS-2) was also analysed using an identical approach. For PPMS-1/PPMS-2, fulfilment was: C1:73.8%/66.7%; C2:72.1%/59.3%; C3:89%/79.2%; C4:96%/92.3%; C5:96%/85.7%; C6:85.8%/78.7%; C7:91%/80.4%. Levels of fulfilment suggest that the use of a single set of criteria for DIS in RRMS and PPMS might be feasible, and reinforce the added value of cerebrospinal fluid (CSF) findings to increase fulfilment in PPMS. Unification of the DIS criteria for both RRMS and PPMS could be considered in further revisions of the MS diagnostic criteria.

Sign in / Sign up

Export Citation Format

Share Document